enGene Therapeutics IncENGN
Price$2.00

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Net Income -$130.4MTTM through 31 Jul 2026
Free Cash Flow -$104MTTM through 31 Jul 2026

Margins

Current

Returns

-56.6%ROE
-45.2%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio10.21x
Net Debt-$41Mnet cash position
Cash & Equivalents$41M

Quality Metrics

Piotroski F-Score1 / 9
Earnings-Beat Rate50.0%

Multi-Year Trend

Diluted EPS-$2.51TTM
'22'23'24'25
FY2025: $2.29

Dividend

No dividend

Capital Allocation

R&D Spend$96.3M

Segment Performance

SegmentRevenueYoYOutlook
Developing genetic medicines$0
View details

Pre-Biologics License Application (BLA) meeting with the FDA and initiation of BLA submission planned for 2H 2026.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.